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Abstract
This report presents evidence for the specificities of select commercially available HOXA4 antibodies in regards to
concerns about the specificity of the HOXA4 antibody used by Lillvis et al. (Regional expression of HOXA4 along
the aorta and its potential role in human abdominal aortic aneurysms. BMC Physiol 2011, 11:9). Using an
antibody characterized extensively by us, Lillvis et al. report detecting HOXA4 at a size of 33 kDa despite our
previous reports that HOXA4 is detected at ~37-39 kDa and that the ~30-33 kDa band is non-specific. Using small
interfering RNA targeting HOXA4, forced expression of full-length HOXA4 and HOXA4-positive and -negative
ovarian cancer cell lines, we confirm our previous findings that the ~30-33 kDa band is non-specific and that
HOXA4 is detected at ~37-39 kDa. Moreover, we demonstrate that HOXA4 small interfering RNA reduces the ~37-
39 kDa HOXA4 band, but not the ~30-33 kDa non-specific band, in a human acute monocytic leukemia cell line
used by Lillvis et al. Western blot analysis performed with two additional commercially available HOXA4 antibodies
also detected HOXA4 at ~37-39 kDa. Lastly, immunofluorescent staining of a HOXA4-negative ovarian cancer cell
line with the antibody used by Lillvis et al. yields strong perinuclear staining, similar to that observed by Lillvis et
al., which cannot be attributed to HOXA4. Our results highlight and briefly discuss the importance of careful
antibody validation and selection for use in various applications.
Correspondence
We read with interest the study of Lillvis et al. [1]
regarding the expression of HOXA4 in the aorta and its
potential role in abdominal aortic aneurysms. The
authors used microarray analysis validated by reverse
transcription quantitative real-time PCR to provide
strong evidence that HOXA4 mRNA levels are reduced
in human abdominal aortic aneurysms relative to con-
trol human abdominal aorta. However, we have signifi-
cant concerns about the subsequent data regarding
HOXA4 protein levels. For their studies Lillvis et al.
used a commercially available rabbit polyclonal HOXA4
antibody (ab26097; Abcam, Cambridge, MA) that was
previously characterized extensively by us [2,3]. While
they were kind enough to reference our studies, they
state that HOXA4 was detected as a single band at ~33
kDa and evidence for this is presented in their Addi-
tional file three, Figure S1A. However, in both of our
previous studies we state that the size of HOXA4 is
~37-39 kDa and our first study [2] demonstrated that
the band at ~30-33 kDa is a non-specific band.
T h e~ 3 0 - 3 3k D an o n - s p e c i f i cb a n di sb yf a rt h em o s t
intense band and appears as a single band at low expo-
sures irrespective of blotting conditions, as was observed
by Lillvis et al. in Additional file three, Figure S1A. This
was demonstrated previously by us [2] and we now pro-
vide additional evidence of this in Figures 1A and 1B.
Strong expression of the ~30-33 kDa non-specific band
is observed in the five human ovarian cancer cell lines
shown in Figures 1A and 1B regardless of the fact that
HOXA4 mRNA is undetectable in both SKOV-3 and
A2780 cells [2,3]. More importantly, the ~30-33 kDa
non-specific band is insensitive to small interfering RNA
( s i R N A )t a r g e t i n gH O X A 4( [ 2 ]a n dF i g u r e1 A )a n d
forced expression of full-length HOXA4 (Figure 1B).
Likewise, Figure 1A shows strong, siRNA-insensitive
expression of the ~30-33 kDa non-specific band in the
acute monocytic leukemia cell line used by Lillvis et al.
(THP-1 cells, designated as MP1 cells by Lillvis et al. in
Additional file four, Table S3).
In contrast, we have demonstrated that the ~37-39
kDa HOXA4 band correlates with HOXA4 mRNA
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reproduction in any medium, provided the original work is properly cited.Figure 1 Evidence for the specificities of select commercially available HOXA4 antibodies. Immunoblot analysis was performed as in [3]
with lysates from one human acute monocytic leukemia (THP-1) and five ovarian cancer (OVCAR-8, OVCAR-3, SKOV-3, A2780 and CaOV-3) cell
lines. Red arrowheads indicate HOXA4 (~37-39 kDa), black arrowheads indicate the ~30-33 kDa non-specific band associated with the Abcam
antibody, and white arrowheads indicate select non-specific bands of equal/greater intensity. (A) SKOV-3 cells lack HOXA4 whereas OVCAR-8 and
OVCAR-3 cells express high levels of HOXA4 [2,3]. Transient knockdown was performed as in [3] with 20 nM HOXA4-targeting siRNA (siHOXA4;
ON-TARGETplus SMARTpool; Dharmacon), control siRNA (siControl; ON-TARGETplus Non-Targeting Pool) or transfection reagent alone (iMAX;
Lipofectamine RNAiMAX). Immunoblot analysis with the Abcam HOXA4 antibody characterized by us [2,3] shows that the ~30-33 kDa non-
specific band detected by Lillvis et al. [1] is insensitive to HOXA4 siRNA and is expressed by HOXA4-negative SKOV-3 cells. (B) A2780 cells lack
HOXA4 whereas CaOV-3 cells express low levels of HOXA4 [2,3]. CaOV-3 cells were transfected as in [3] with control vector (CaOV-3-Vector) or
vector encoding full-length HOXA4 (CaOV-3-HOXA4). Immunoblot analysis with the Abcam antibody and two other commercially available
HOXA4 antibodies shows that the ~37-39 kDa HOXA4 band detects exogenously expressed HOXA4 and is undetectable in HOXA4-negative
A2780 cells. (C) Formaldehyde-fixed SKOV-3 cells were permeabilized, blocked and incubated overnight with anti-HOXA4 (1:3200). Secondary
antibody was applied, cell nuclei were stained with Hoechst 33258, and coverslips were examined by epifluorescence microscopy. Although
HOXA4 mRNA [2,3] and protein (A) are undetectable in SKOV-3 cells, these cells have strong expression of the ~30-33 kDa non-specific band ((A)
and [2]). Note that immunofluorescent staining of HOXA4-negative SKOV-3 cells with the Abcam antibody yields strong perinuclear staining
which cannot be attributed to HOXA4.
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genously expressed HOXA4 ([2,3] and Figures 1A and
1B). Although the ~37-39 kDa HOXA4 band is
expressed at very low levels in THP-1 cells, it is the
only band that is reduced by treatment with HOXA4
siRNA (Figure 1A). Furthermore, we now provide evi-
dence that two additional commercially available
HOXA4 antibodies detect a ~37-39 kDa band that cor-
relates with HOXA4 mRNA levels and detects exogen-
ously expressed HOXA4 (Figure 1B). In this context, we
are not convinced that the Western blot results pre-
sented by Lillvis et al. reflect changes in HOXA4 protein
levels. In light of their convincing mRNA data, perhaps
a re-examination of the results of longer exposures
would allow Lillvis et al. to quantify the ~37-39 kDa
HOXA4 band detected with this antibody. We routinely
cut away the membrane just below the 37 kDa molecu-
lar mass marker prior to immunoblotting in order to
prevent strong signal from the ~30-33 kDa non-specific
band from interfering with quantitation of the ~37-39
kDa HOXA4 band.
Our second, and very much related, concern has to do
with the use of the same rabbit polyclonal HOXA4 anti-
body for immunohistochemistry and immunofluores-
cence. In light of the intense ~30-33 kDa non-specific
band and additional ~46-48 kDa non-specific bands of
equal or greater intensity than HOXA4, we have signifi-
cant concerns about the use of this antibody in these
types of applications. Indeed, we have performed immu-
nofluorescent staining of HOXA4-negative SKOV-3 cells
([2,3] and Figure 1A) and found strong perinuclear
staining similar to that observed by Lillvis et al. which
cannot be attributed to HOXA4 since SKOV-3 cells
don’t express HOXA4 (Figure 1C). While this staining
most likely corresponds to the ~30-33 kDa non-specific
band due to its intensity and the high dilution of the
antibody (1:3200 vs. 1:200 used by Lillvis et al.), we can-
not rule out contributions from the ~46-48 kDa non-
specific bands. Nuclear localization, especially as
assessed by epifluorescence rather than confocal micro-
scopy, does not appear to be sufficient to identify
HOXA4 in cells with demonstrated HOXA4 expression
since Lillvis et al. also report detecting the ~30-33 kDa
band in both cytoplasmic and nuclear fractions by Wes-
tern blot.
In this context, we are not convinced that the immu-
nohistochemistry and immunofluorescence results pre-
sented by Lillvis et al. accurately depict the localization
of HOXA4 protein. Indeed, we would suggest that the
use of this rabbit polyclonal HOXA4 antibody in these
types of applications is unwarranted unless definitive
validation of specificity is presented. Our preliminary
Western blot analysis of two additional commercially
available HOXA4 antibodies has similarly revealed a
number of non-specific bands of equal or greater inten-
sity than HOXA4 (Figure 1B). Persuasive validation stu-
dies will therefore be required to establish whether any
of the commercially available HOXA4 antibodies possess
the specificity required for use in applications such as
immunohistochemistry and immunofluorescence. Future
studies on the biology of HOXA4 and its roles in dis-
ease would benefit greatly from the development of a
h i g h l ys p e c i f i ca n t i b o d ys u i t a b l ef o ru s ei nt h e s ea n d
other applications.
The example of HOXA4 highlights the need for
researchers to validate the specificity of antibodies for
use in various applications, especially in the absence of
rigorous antibody characterization. Indeed, while the
Abcam HOXA4 antibody performs very well in Western
blot analysis, its use in other applications such as immu-
nocytochemistry, immunohistochemistry or immunopre-
cipitation is likely unwarranted unless definitive
validation studies are performed in consideration of the
sheer intensity of the signal from the ~30-33 kDa pro-
tein. For many companies antibody characterization
takes the form of ELISA or Western blot analysis with
the antigenic peptide/protein. While this does establish
whether or not the antibody can detect the particular
peptide/protein against which it was raised, it does not
prove it will detect the actual protein (except when
raised and tested against full-length protein) nor does it
address how the antibody will perform in the context of
the entire proteome (i.e. in cells or tissues) or in differ-
ent applications. Preabsorption studies with the anti-
genic peptide/protein can identify true non-specific
bands (i.e. cannot be eliminated by saturation), but they
cannot distinguish the protein of interest from non-spe-
cific proteins with similar epitopes that the antibody
binds to in a specific manner. For example, preabsorp-
tion of the Abcam HOXA4 antibody with the antigenic
peptide completely eliminates the ~37-39 kDa HOXA4
band, the ~30-33 kDa non-specific band and one of the
~46-48 kDa non-specific bands [2]. Thus, the other
~46-48 kDa non-specific band is likely a true non-speci-
fic band, yet this approach fails to identify only the ~37-
39 kDa band as being specific for HOXA4.
The detection of a band of “appropriate” size in cell or
tissue lysates can be used to confirm the identity of a
band, but must involve more than one (preferably three
or more) lysates from cells or tissues known to have dif-
fering basal or experimentally manipulated expression
levels. In general, accurate up-front knowledge of
expression levels is most easily achieved by measuring
mRNA levels. An obvious, and highly effective, exten-
sion of this approach is to use RNA interference-
mediated knockdown or vector-based forced expression
to generate lysates with gene-specific changes in the
expression level of the protein of interest. Although use
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validation for each application, many of the approaches
discussed above can be adapted to different applications.
In addition, companies are beginning to employ these
approaches as they strive to market gene-specific pro-
duct portfolios (antibody, protein/peptide, RNA interfer-
ence and forced expression) on a genome-wide scale.
However, in the absence of thorough antibody charac-
terization it is ultimately the responsibility of the
researcher to ensure the validity of results obtained
from antibody-based applications.
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